Positive Topline Results For Autoimmune Disorders Reported By This Major Biotech Company

Groundbreaking Results: Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of Oral Anti-Interleukin 12/23 Antibody (RT-111).

Disclaimer: This article includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

In a significant breakthrough, Rani Therapeutics Holdings, Inc., a pioneering biotechnology company, has announced positive topline results from its Phase 1 clinical study of RT-111, a RaniPill capsule cont…